University Hospital of A Coruña
Welcome,         Profile    Billing    Logout  
 0 Trials 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Calles, Antonio
ALKALINE, NCT04127110 / 2019-003862-41: Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients

Active, not recruiting
2
68
Europe, RoW
Lorlatinib
European Organisation for Research and Treatment of Cancer - EORTC, European Organisation for the Research and Treatment of Cancer, Pfizer NV/SA, European Organization for the Research and Treatment of Cancer (EORTC)
Non Small Cell Lung Cancer
07/24
11/24
LUPER, NCT04358237 / 2019-002261-35: Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer.

Active, not recruiting
1/2
28
Europe
Lurbinectedin, PM01183, Zepsyre, Pembrolizumab, Keytruda
Antonio Calles Blanco, MedSIR, PharmaMar, Merck Sharp & Dohme LLC
Small Cell Lung Carcinoma
09/23
03/25
RAMP 203, NCT05074810: Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

Recruiting
1/2
153
Europe, US
avutometinib and sotorasib, AMG 510, LUMAKRAS™, VS-6766, avutometinib and sotorasib and defactinib, VS-6063
Verastem, Inc., Amgen
Non Small Cell Lung Cancer, KRAS Activating Mutation
09/25
04/27
METex14, NCT04868877 / 2021-000203-20: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Recruiting
1/2
576
Europe, US, RoW
MCLA-129, bispecific, Osimertinib, Tagrisso, Chemotherapy
Merus N.V.
Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
03/26
03/27
ARROS-1, NCT05118789 / 2021-002477-26: A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement

Recruiting
1/2
359
Europe, Canada, Japan, US, RoW
NVL-520
Nuvalent Inc., Nuvalent, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
10/25
10/26
ALKOVE-1, NCT05384626 / 2022-000122-21: A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation

Recruiting
1/2
470
Europe, Canada, Japan, US, RoW
NVL-655
Nuvalent Inc., Nuvalent, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
02/26
03/26
LORLAPULM, NCT05167500: Efficacy & Safety Study of Lorlatinib in ALK/ROS1 Metastatic NSCLC Patients With Compassionate Use Treatment

Completed
N/A
118
Europe
Lorlatinib, Lorviqua
Fundación GECP
Metastatic Non Small Cell Lung Cancer
12/22
12/22
NCT02941458: Thoracic Tumours Register

Recruiting
N/A
10000
Europe
Spanish Lung Cancer Group
Thoracic Tumors
12/25
12/30

Download Options